Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes

RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer (NSCLC) treatment, thanks to their efficacy and safety profiles. This class of medications currently represents the standard of c...

Full description

Bibliographic Details
Main Authors: Danilo Rocco, Luigi Sapio, Luigi Della Gravara, Silvio Naviglio, Cesare Gridelli
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:International Journal of Molecular Sciences
Subjects:
NSCLC
RET fusion
TKI
drug resistance
Online Access:https://www.mdpi.com/1422-0067/24/3/2433

Internet

https://www.mdpi.com/1422-0067/24/3/2433

Similar Items